Harvard Researchers probe Cancer genetics to target patient treatments

Genetic information about specific cancer can lead to better patient treatments

Levi Garraway says having genetic information about many cancers can lead to targeted treatments for patients.

Cancers, long defined primarily by where they arose (breast, lung, blood cells, brain) are proving to be as individual as faces: increasingly defined, scientists are discovering, by their unique genetic and molecular makeup. This ability to understand the genetics of individual cancers is changing the way the disease is treated. At Harvard and elsewhere, medical centers are investing in research tools to study cancer’s genetic features, and determining how best to apply the new knowledge in the clinic. This is part of a larger movement toward personalized or precision medicine, which aims to tailor disease prevention and treatment as much as possible to an individual patient.

That goal remains far off for most diseases, but rapid progress has been made against cancer, in which changes in genes are a defining feature. In some cases, inherited genes put people at higher risk. But more often, cancer arises from so-called somatic mutations: genetic changes and errors that occur within specific cells during a lifetime. These mutations allow cancer cells to proliferate, spread, and, in some cases, persist despite treatment.

Levi Garraway, associate professor of medicine at the Dana-Farber Cancer Institute (DFCI) and Broad Institute, says converging developments in the past few years have brought precision in cancer care closer than ever before. First, “The armamentarium of targeted agents in clinical trials is much larger,” he reports. The initial “targeted” cancer drug, Gleevec, was approved more than a decade ago; unlike chemotherapy drugs that kill cancer cells but can also be toxic to normal cells, Gleevec is designed to bind to and block an enzyme that’s produced only by cancer cells with a specific genetic mutation found in patients with chronic myelogenous leukemia (CML) and some other cancers. (For a physician’s account of the development and early use of Gleevec, see “Ken’s Story,” January-February 2007, page 36.) Researchers in academia and industry have since focused on discovering other important genetic mutations in cancer cells, developing agents to target those mutations, and testing those drugs.

Depending on the type of tumor, “a substantial proportion [of cases]—half or more—have a genetic alteration that a clinician might want to know about,” Garraway explains—either because a drug targeting that mutation is approved or in clinical trials, or because the mutation indicates that a certain treatment wouldn’t be effective in that patient. Researchers have found that the same mutations may be involved in widely different cancers, so a drug developed to target a mutation common in one type of cancer may also help a subset of patients with another type of cancer that shares that mutation. Gleevec, for instance, was developd for CML and then approved for a type of gastrointestinal tumor, and is being tested in patients with brain and soft-tissue cancers that show the same mutation.

Second, just as anticancer-drug development is accelerating, the cost of genetic sequencing is plummeting. Sequencing the entire genome of individual patients’ cancer is still not feasible, but tests can analyze a set of important or clinically relevant genetic mutations. Garraway says the technology to characterize cancers is advancing rapidly, but “it’s going to take a while to really understand how to use” that knowledge. The solution, he says, is more information: “We need to query each tumor and make sense of how that tumor was built.” George Demetri, professor of medicine at Harvard Medical School and senior vice president for experimental therapeutics at DFCI, believes that academia has an important role to play in this early-stage research to find promising targets; the pharmaceutical industry, he says, is “looking more to academia to make discoveries that we can work on together.”

Ideally, it would be possible to characterize each patient’s tumor and prescribe an individually tailored cocktail of targeted medicines aimed at the malignancy, plus new drugs designed to stimulate the immune system against the disease. But Demetri admits that this goal is challenging. Cancers are genetically unstable; they may have a chaotic mix of changes in DNA, RNA, and other molecules that complicate the task of researchers trying to determine what is truly crucial to target. And not all alterations can be easily targeted with a drug. Even obtaining material to profile can be a challenge: cells in one part of a tumor may be genetically distinct from cells in another part. (Demetri’s group recently announced a method to characterize specific mutations in one type of tumor using a blood test, rather than an invasive biopsy.) Finally, targeted cancer therapies are also expensive, so some scientists have questioned the feasibility of developing cocktails of drugs as part of routine medical care.

 Nevertheless, academic medical centers are building resources to facilitate precision medicine. Beth Israel Deaconess Medical Center is developing a national curriculum to train pathology residents in genomic techniques, to better prepare them to use new molecular-based tests. DFCI and Brigham and Women’s Hospital are amassing one of the world’s largest databases of cancer genetic abnormalities by surveying large numbers of patient tumors for 471 mutations in 41 different genes. The Translational Research Laboratory at Massachusetts General Hospital focuses on applying such research directly to clinical care: it now offers a molecular “fingerprinting” service to patients with certain cancers for which targeted drugs are available. It’s not yet clear how these new technologies will be incorporated into routine care, but many experts are hopeful that they will lead to new ways of defining and attacking a disease that worldwide kills more than 7 million people a year.

Read more articles by Courtney Humphries
Related topics

You might also like

In Sermon, Garber Urges Harvard Community to ‘Defend and Protect’ Institutions

Harvard’s president uses traditional Memorial Church address to encourage divergent views.

A New Narrative of Civil Rights

Political philosopher Brandon Terry’s vision of racial progress

This Astronomer is Sounding a Warning on 'Space Junk'

As debris accumulates in low Earth orbit, the danger of destructive collisions continues to rise.

Most popular

Is the Constitution Broken?

Harvard legal scholars debate the state of our founding national document.

Paolo Pasco and the art of making crosswords

Paolo Pasco and the art of making crosswords

Harvard Research Funding Will Resume, Government Signals

Notices of grant reinstatements follow a court ruling, but the Trump administration could still appeal. 

Explore More From Current Issue

Man splashing water on his face at outdoor fountain beside woman holding cup near stone building.

Why Heat Waves Make You Miserable

Scientists are studying how much heat and humidity the human body can take.

James Muller in white lab coat leaning on railing in hospital hallway.

Free Speech, the Bomb—and Donald Trump

A Harvard cardiologist on the unlikely alliances that shaped a global movement to prevent nuclear war

Catherine Zipf smiling, wearing striped shirt and dark sweater outdoors.

Preserving the History of Jim Crow Era Safe Havens

Architectural historian Catherine Zipf is building a database of Green Book sites.